

CHRONIC ANGINA

COSTS MORE

than you think

Effectively addressing chronic angina symptoms can improve not only the quality of life but also the long-term outlook of coronary disease patients all while significantly

REDUCING HEALTHCARE COST


Let's take a look



The chronic angina patient population is growing faster than you think

In just a single decade, the number of
CHRONIC ANGINA PATIENTS IN THE U.S.
has risen

from **7.8M¹** to **11.1M^{2,3}**



A rising tide
of cardiac risk – and cost...

References:

1. Go AS et al. *Circulation*. 2013;127:143-52.
2. Virani et al. *Circulation*. 2023;148:e9-e119.
3. Tsao CW, Aday AW, Almarazooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. *Circulation*. 2022;145:e153-e639.



Chronic angina treatment costs MORE than space exploration

THE ANNUAL TOTAL DIRECT COST
OF MANAGING CHRONIC ANGINA IN THE U.S.
HAVE BALLOONED
TO AN AVERAGE ESTIMATED
53 BILLION^{1,2}



Mean annual total US costs associated with chronic stable angina

- Key cost drivers include revascularization procedures, hospital admissions and frequent ER visits.³
- Costs for patients with stable coronary disease with chronic stable angina are twice as high as those for patients with coronary disease without angina.^{4,5,6}

That is as much as NASA would spend
in 2 Years³

References:

1. Virani SS et al. *Circulation*. 2023;148:e9-e119.
2. Adapted from: Reynolds MW et al. *Am J Manag Care*. 2004;10:S347-S357. [Cost estimated updated to 2024 chronic angina prevalence].
3. National Aeronautics and Space Administration (NASA). Financial Year 2024 Appropriations P.L.118-42. June 2024. At: <https://www.nasa.gov/wpcontent/uploads/2024/07/fy-2024-spend-plan-june-2024.pdf>. Accessed: June 15, 2025.
4. Kempf J et al. *Am Health Drug Benefits*. 2011;4(6):353-361.
5. Ben-Yehuda O et al. *Am Health Drug Benefits*. 2011;4(6):353-361.
6. Bress AP et al. *Am J Cardiol*. 2018;122:1809-16.



Chest pain visits are on the rise in the U.S.,
reflecting the growing prevalence
of chronic angina

CHEST PAIN
IS THE 2ND MOST COMMON CAUSE
OF ER VISITS NATIONWIDE
BUT ONLY 4% LEAD TO HOSPITAL ADMISSION¹

8.3 million ER visits annually
for chest pain in 2022²
up 10% since 2016³

References:

1. Aalam AA, et al. *Emerg Med J*. 2020;0:1-4.
2. National Hospital Ambulatory Medical Care Survey: 2022. Emergency Department Summary Table. US Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics. 2022.
3. National Hospital Ambulatory Medical Care Survey: 2016. Emergency Department Summary Table. US Department of Health and Human Services. Centers for Disease Control and Prevention. National Center for Health Statistics. 2016.




**A large majority
of chest pain-related ER visits
in chronic angina patients could be avoided**

**A single chest pain-related ER visit
COSTS MEDICARE
OVER \$1,000**

- A large proportion of these ER visits **are caused by inadequate drug therapy**
- Effective pharmacological management of both chronic angina symptoms and risk factors **is critical for improving prognosis and longevity**

References:

1. Maron DJ et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. *N Engl J Med*. 2020;382;:395-407.
2. Boden W et al. *N Engl J Med*. 2007;356(15):1503-16.
3. Lipinska Zielinska A, Zielinska M. *E-Journal of Cardiology Practice*. 2017;15(4).
4. Barbero U et al. *Scientifica (Cairo)*. 2016;2016:3769152.



Auxilius Pharma's mission is to develop a cost effective solution to the treatment of angina

WE REANALYZED THE HEALTH ECONOMIC FINDINGS OF THE IONA STUDY IN THE SETTING OF THE REALITIES OF DRUG TREATMENT OF CHRONIC ANGINA IN THE U.S. TODAY

Our work demonstrates substantial opportunity for cost reductions with its unique anti-anginal drug combination

- The IONA Study is the second largest randomized outcome trial of an anti-anginal drug in patients with symptomatic stable angina.^{1,2}
- Its results demonstrated that optimized medical treatment of chronic angina can yield reductions in the use of hospital services utilization and cost.³
- IONA also demonstrates, for the first time, that its unique anti-anginal drug regimen can combine effective angina symptom relief with reductions in cardiovascular events.^{3,4}

References:

1. IONA Study Group. *Lancet*. 2002;359:1269-75.
2. Walker A et al. *Heart*. 2006;92:619-24.
3. Poole-Wilson PA et al. *Lancet*. 2004;364(9437):849-57.
4. IONA Study Group. *Am Heart J*. 2005;150:689:e1-689.e9.



Jed Litwiniuk, MHA
CEO

Dawid Chabowski, PhD
Science & Operational Manager